Tags

Type your tag names separated by a space and hit enter

Aspirin use and pancreatic cancer risk.
Eur J Cancer Prev 2010; 19(5):352-4EJ

Abstract

Preclinical findings suggest that aspirin might inhibit pancreatic carcinogenesis, but epidemiological data are scanty and controversial. The role of aspirin use in pancreatic cancer is further analyzed in a multicentric hospital-based case-control study conducted in Italy between 1991 and 2008. Cases were 308 patients with incident pancreatic cancer and controls were 477 patients admitted to the same hospitals as cases for acute conditions, not related to risk factors for pancreatic cancer. A total of 22 cases (7%) and 37 controls (8%) reported regular aspirin use, with a corresponding adjusted odds ratio (OR) of 0.87 [95% confidence interval (CI): 0.47-1.61]. A slight protection, although not significant, was observed for duration of use > or =5 years (OR=0.53; 95% CI: 0.21-1.33) and for time since first use > or =10 years (OR=0.69; 95% CI: 0.25-1.93). The risk of pancreatic cancer was significantly below unity for current users of > or =5 years (OR=0.23; 95% CI: 0.06-0.90), but the risk was based on three cases and 16 controls only. We observed no association between regular aspirin use and pancreatic cancer risk, although our results suggested a possible protective effect for long-term current users.

Authors+Show Affiliations

Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

20502343

Citation

Bonifazi, Martina, et al. "Aspirin Use and Pancreatic Cancer Risk." European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), vol. 19, no. 5, 2010, pp. 352-4.
Bonifazi M, Gallus S, Bosetti C, et al. Aspirin use and pancreatic cancer risk. Eur J Cancer Prev. 2010;19(5):352-4.
Bonifazi, M., Gallus, S., Bosetti, C., Polesel, J., Serraino, D., Talamini, R., ... La Vecchia, C. (2010). Aspirin use and pancreatic cancer risk. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), 19(5), pp. 352-4. doi:10.1097/CEJ.0b013e32833b48a4.
Bonifazi M, et al. Aspirin Use and Pancreatic Cancer Risk. Eur J Cancer Prev. 2010;19(5):352-4. PubMed PMID: 20502343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aspirin use and pancreatic cancer risk. AU - Bonifazi,Martina, AU - Gallus,Silvano, AU - Bosetti,Cristina, AU - Polesel,Jerry, AU - Serraino,Diego, AU - Talamini,Renato, AU - Negri,Eva, AU - La Vecchia,Carlo, PY - 2010/5/27/entrez PY - 2010/5/27/pubmed PY - 2010/11/9/medline SP - 352 EP - 4 JF - European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) JO - Eur. J. Cancer Prev. VL - 19 IS - 5 N2 - Preclinical findings suggest that aspirin might inhibit pancreatic carcinogenesis, but epidemiological data are scanty and controversial. The role of aspirin use in pancreatic cancer is further analyzed in a multicentric hospital-based case-control study conducted in Italy between 1991 and 2008. Cases were 308 patients with incident pancreatic cancer and controls were 477 patients admitted to the same hospitals as cases for acute conditions, not related to risk factors for pancreatic cancer. A total of 22 cases (7%) and 37 controls (8%) reported regular aspirin use, with a corresponding adjusted odds ratio (OR) of 0.87 [95% confidence interval (CI): 0.47-1.61]. A slight protection, although not significant, was observed for duration of use > or =5 years (OR=0.53; 95% CI: 0.21-1.33) and for time since first use > or =10 years (OR=0.69; 95% CI: 0.25-1.93). The risk of pancreatic cancer was significantly below unity for current users of > or =5 years (OR=0.23; 95% CI: 0.06-0.90), but the risk was based on three cases and 16 controls only. We observed no association between regular aspirin use and pancreatic cancer risk, although our results suggested a possible protective effect for long-term current users. SN - 1473-5709 UR - https://www.unboundmedicine.com/medline/citation/20502343/Aspirin_use_and_pancreatic_cancer_risk_ L2 - http://Insights.ovid.com/pubmed?pmid=20502343 DB - PRIME DP - Unbound Medicine ER -